These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 35303014)
1. A Bayesian network meta-analysis of the primary definitive therapies for locoregionally advanced nasopharyngeal carcinoma: IC+CCRT, CCRT+AC, and CCRT alone. Zhang ZJ; Shi LL; Hong XH; Xiao BY; Lin GH; Liu Q; Wang BC PLoS One; 2022; 17(3):e0265551. PubMed ID: 35303014 [TBL] [Abstract][Full Text] [Related]
2. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Chen YP; Wang ZX; Chen L; Liu X; Tang LL; Mao YP; Li WF; Lin AH; Sun Y; Ma J Ann Oncol; 2015 Jan; 26(1):205-211. PubMed ID: 25355717 [TBL] [Abstract][Full Text] [Related]
3. Optimal induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: an update Bayesian network meta-analysis. Wu Q; Li S; Liu J; Zhong Y Eur Arch Otorhinolaryngol; 2022 Nov; 279(11):5057-5069. PubMed ID: 35767064 [TBL] [Abstract][Full Text] [Related]
4. Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials. Fang L; Shi L; Wang W; Hu T; Rao X Eur Arch Otorhinolaryngol; 2021 Oct; 278(10):3633-3642. PubMed ID: 33598731 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis. Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410 [TBL] [Abstract][Full Text] [Related]
6. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966 [TBL] [Abstract][Full Text] [Related]
7. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. Mu X; Liu H; Wu J; Chen S; Peng X; Wang J; Wei Z; He L; Liu J; Lu Z; Su Y Aging (Albany NY); 2022 Aug; 14(16):6727-6739. PubMed ID: 36036759 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers. Tao HY; He F; Shi QY; Liu R; Wang ZL; Du KP; Li JF; Liu H; Lu ZQ; Zhang JJ; Bai YH Cancer Med; 2023 Mar; 12(6):6811-6824. PubMed ID: 36420689 [TBL] [Abstract][Full Text] [Related]
9. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study. Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950 [TBL] [Abstract][Full Text] [Related]
10. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis. Li Y; Tang LQ; Liu LT; Guo SS; Liang YJ; Sun XS; Tang QN; Bei JX; Tan J; Chen S; Ma J; Zhao C; Chen QY; Mai HQ Cancer Res Treat; 2018 Oct; 50(4):1304-1315. PubMed ID: 29334605 [TBL] [Abstract][Full Text] [Related]
11. Induction Chemotherapy Improved Long Term Outcomes in Stage IV Locoregional Advanced Nasopharyngeal Carcinoma. Wang YW; Ho SY; Lee SW; Chen CC; Litsu S; Huang WT; Yang CC; Lin CH; Chen HY; Lin LC Int J Med Sci; 2020; 17(5):568-576. PubMed ID: 32210706 [No Abstract] [Full Text] [Related]
12. The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis. Zhong Q; Luo D; Li X; Du Q; Liang Q; Liu W; Li J; Zhu X Cancer Biol Ther; 2023 Dec; 24(1):2274121. PubMed ID: 37965924 [TBL] [Abstract][Full Text] [Related]
13. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial. Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190 [TBL] [Abstract][Full Text] [Related]
14. Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial. Zhang Y; Li WF; Liu X; Chen L; Sun R; Sun Y; Liu Q; Ma J Radiother Oncol; 2018 Oct; 129(1):18-22. PubMed ID: 29258695 [TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis. Wang BC; Xiao BY; Lin GH; Wang C; Liu Q BMC Cancer; 2020 May; 20(1):393. PubMed ID: 32375701 [TBL] [Abstract][Full Text] [Related]
16. Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. Chen YP; Tang LL; Yang Q; Poh SS; Hui EP; Chan ATC; Ong WS; Tan T; Wee J; Li WF; Chen L; Ma BBY; Tong M; Tan SH; Cheah SL; Fong KW; Sommat K; Soong YL; Guo Y; Lin AH; Sun Y; Hong MH; Cao SM; Chen MY; Ma J Clin Cancer Res; 2018 Apr; 24(8):1824-1833. PubMed ID: 29431618 [No Abstract] [Full Text] [Related]
17. A network meta-analysis for efficacies and toxicities of different therapeutic regimens in the treatment of advanced nasopharyngeal carcinoma. Li T; Yang F; Ma K; Lv L Eur Arch Otorhinolaryngol; 2021 Sep; 278(9):3333-3344. PubMed ID: 33517538 [TBL] [Abstract][Full Text] [Related]
18. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis. Tang SQ; Xu C; Wang XS; Tang LL; Li WF; Chen L; Mao YP; Guo R; Liu Q; Sun Y; Ma J Oral Oncol; 2020 Jun; 105():104686. PubMed ID: 32283514 [TBL] [Abstract][Full Text] [Related]
19. Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching. Liu ZC; Zeng KH; Gu ZB; Chen RP; Luo YJ; Tang LQ; Zhu KB; Liu Y; Sun XS; Zeng L Radiother Oncol; 2023 Jan; 178():109421. PubMed ID: 36410548 [TBL] [Abstract][Full Text] [Related]
20. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model. Liu W; Yu B; Luo Y; Li J; Yuan X; Wu S; Liang B; Lv Z; Li Y; Peng X; Lu J; Peng X; Liu X BMC Cancer; 2021 May; 21(1):639. PubMed ID: 34051750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]